In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 8, 2005, Pages 3239-3250

  Koga, Tetsufumi ^a   Abe, Tomomi ^a   Inoue, Harumi ^a   Takenouchi, Takashi ^a   Kitayama, Akiko ^a   Yoshida, Tatsuhiko ^a   Masuda, Nobuhisa ^a   Sugihara, Chika ^a   Kakuta, Masayo ^a   Nakagawa, Miyuki ^a   Shibayama, Takahiro ^a   Matsushita, Yoko ^a   Hirota, Takashi ^a   Ohya, Satoshi ^a   Utsui, Yukio ^a   Fukuoka, Takashi ^a   Kuwahara, Syogo ^b  

^a DAIICHI SANKYO CO   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPICILLIN; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CS 023; IMIPENEM; LEVOFLOXACIN; MEROPENEM; UNCLASSIFIED DRUG; VANCOMYCIN;

AMPICILLIN RESISTANT HAEMOPHILUS INFLUENZAE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; IN VIVO STUDY; LUNG INFECTION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS EPIDERMIDIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PENICILLIN RESISTANT STREPTOCOCCUS PNEUMONIAE; PRIORITY JOURNAL; PROTEUS VULGARIS; PSEUDOMONAS AERUGINOSA;

ANIMALS; ANTI-BACTERIAL AGENTS; CARBAPENEMS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS;

EID: 23044456601     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.8.3239-3250.2005     Document Type: Article

References (27)

1. Bliss, C. I. 1934. The method of probits. Science 79:38-39.
2. Boxenbaum, H. 1984. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab. Rev. 15:1071-1121.
3. Clissold, S. P., P. A. Todd, and D. M. Campoli-Richards. 1987. Imipenem/ cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 33:183-241.
4. Edwards, J. R. 1995. Meropenem: a microbiological overview. J. Antimicrob. Chemother. 36(Suppl. A):1-17.
5. Fukuoka, T., H. Kawada, A. Kitayama, T. Koga, M. Kubota, T. Harasaki, Y. Kamai, S. Ohya, H. Yasuda, M. Iwata, and S. Kuwahara. 1998. Efficacy of CS-834 against experimental pneumonia caused by penicillin-susceptible and -resistant Streptococcus pneumoniae in mice. Antimicrob. Agents Chemother. 42:23-27.
6. Fukuoka, T., K. Puchler, J. Rennecke, and S. Kuwahara. 2000. In vitro activity of CS-023 against European clinical relevant bacterial isolates, abstr. F-326. In Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
7. Goa, K. L., and S. Noble. 2003. Panipenem/betamipron. Drugs 63:913-925.
8. Hamajima, K., H. Kobayashi, K. Kamei, M. Shibata, J. Horikoshi, and K. Hayase. 1985. Plasma levels and urinary excretion of imipenem and cilastatin sodium in dogs and rabbits. Chemotherapy (Tokyo) 33(Suppl. 4):315-328.
9. Hikida, M., S. Terashima, Y. Sato, R. Okamoato, and M. Inoue. 2001. Comparative antibacterial activity of carbapenems against P. aeruginosa (1). Jpn. J. Antibiot. 54:571-579.
10. Hisaoka, M., M. Ichikawa, and T. Terao. 1991. Microbiological assay method for the determination of panipenem concentration in body fluids. Chemotherapy (Tokyo) 39(Suppl. 3):190-196.
11. Kobayashi, Y., and T. Matsushima. 2003. Clinical analysis of patients requiring long-term mechanical ventilation of over three months: ventilator-associated pneumonia as a primary complication. Intern. Med. 42:25-32.
12. Moine, P., E. Vallee, E. Azoulay-Dupuis, P. Bourget, J. P. Bedos, J. Bauchet, and J. J. Pocidalo. 1994. In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia model. Antimicrob. Agents Chemother. 38:1953-1958.
13. Nakagawa, K., and M. Koyama. 1985. Imipenem, cilastatin sodium, imipenem/cilastatin sodium clinical phase 1 study. Chemotherapy (Tokyo) 33(Suppl. 4):357-378.
14. National Committee for Clinical Laboratory Standards. 1997. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 4th ed., approved standard M11-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
15. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed., approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
16. Okumura, K., H. Tsuiji, K. Takeda, I. Fukuda, T. Nagaki, M. Takano, K. Higo, and J. Kinami. 1983. Absorption, distribution metabolism and excretion of ceftazidime in mice, rats and rabbits. Chemotherapy (Tokyo) 31(Suppl. 3):188-198.
17. Osano, E., Y. Arakawa, R. Wacharotayankun, M. Ohta, T. Horii, H. Ito, F. Yoshimura, and N. Kato. 1994. Molecular characterization of an enterobacterial metallo β-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance. Antimicrob. Agents Chemother. 38:71-78.
18. Rennecke, J., T. Hirota, T. Shibayama, Y. Matsushita, S. Kuwahara, K. Puchler, A. Ruhland, and B. Drewelow. 2002. Safety, tolerability, and pharmacokinetics (PK) of CS-023, a new parenteral carbapenem, in healthy male volunteers, abstr. F-327. In Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington, D.C.
19. Saito, A. 1992. Pharmacokinetic study on meropenem. Chemotherapy (Tokyo) 40(Suppl. 1):276-282.
20. Shibayama, T., N. Matsushita, N. Kikuchi, K. Kawai, T. Hirota, and S. Kuwahara. 2000. R-115685, a novel parenteral carbapenem: pharmacokinetic and metabolism in laboratory animals, abstr. F-1233. In Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington, D.C.
21. Sumita, Y., H. Nouda, E. Tada, T. Kohzuki, M. Kato, T. Okuda, and M. Fukasawa. 1992. Pharmacokinetics of meropenem, a new carbapenem antibiotic, parenterally administrated to laboratory animals. Chemotherapy (Tokyo) 40(Suppl. 1):123-131.
22. Takenouchi, T., Y. Ishii, and K. Yamaguchi. 2002. Properties of extended-spectrum β-lactamases constructed by site-directed mutagenesis. J. Infect. Chemother. 8:211-217.
23. Thomson, K. S., and E. S. Moland. 2004. CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa. J. Antimicrob. Chemother. 54:557-562.
24. Tsuji, M., Y. Ishii, A. Ohno, S. Miyazaki, and K. Yamaguchi. 1998. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob. Agents Chemother. 42:94-99.
25. Waley, S. G. 1974. A spectrophotometric assay of β-lactamase action on penicillins. Biochem. J. 139:789-790.
26. Wise, R., A. P. Gillett, B. Cadge, S. R. Durham, and S. Baker. 1980. The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics. J. Infect. Dis. 142:77-82.
27. Wiseman, L. R., A. J. Wagstaff, R. N. Brogden, and H. M. Bryson. 1995. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 50:73-101.